View printer-friendly version |
Charles River Opens New Biomedical Diagnostic Facility
New facility provides opportunity to utilize innovative technology platforms that support drug development
"Our new facility provides Charles River with additional capacity for growth, as well as the capability to utilize innovative technology platforms to advance the high-quality R&D services we provide our biopharmaceutical and academic clients," said
Charles River is one of the largest global preclinical contract research organizations, or CROs, with approximately 1,000 employees in
About Charles River
Accelerating Drug Development. Exactly. Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them. To learn more about our unique portfolio and breadth of services, visit http://www.criver.com.
Source:
Charles River Laboratories, Inc.
Investors:
Susan E. Hardy, 781-222-6190
Corporate Vice President, Investor Relations
susan.hardy@crl.com
or
Media:
Amy Cianciaruso, 781-222-6168
Director, Public Relations
amy.cianciaruso@crl.com